lapatinib has been researched along with entinostat in 5 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (entinostat) | Trials (entinostat) | Recent Studies (post-2010) (entinostat) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 557 | 31 | 402 |
| Protein | Taxonomy | lapatinib (IC50) | entinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 1.5547 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.73 | |
| Tissue factor | Homo sapiens (human) | 8 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3.93 | |
| Histone deacetylase 4 | Homo sapiens (human) | 2.5077 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1.0631 | |
| Histone deacetylase 7 | Homo sapiens (human) | 2.7679 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1.4517 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 3.1451 | |
| Histone deacetylase 11 | Homo sapiens (human) | 3.3762 | |
| Histone deacetylase 8 | Homo sapiens (human) | 3.5118 | |
| Histone deacetylase 6 | Homo sapiens (human) | 2.9645 | |
| Histone deacetylase 9 | Homo sapiens (human) | 2.9949 | |
| Histone deacetylase 5 | Homo sapiens (human) | 2.7109 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.94 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 1.185 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Chen, M; Hu, L; Yang, X; Zhang, Q | 1 |
| Bartholomeusz, C; Hortobagyi, GN; Humphries, J; Lee, J; Mansour, O; Ordentlich, P; Ueno, NT | 1 |
| Alvarez, R; Barcenas, CH; Booser, DJ; Brewster, AM; Brown, PH; Davis, DW; Giordano, SH; Ibrahim, NK; Iwase, T; Jackson, SA; Lee, J; Lim, B; Moscow, JA; Moulder, SL; Murthy, RK; Piekarz, R; Shen, Y; Tripathy, D; Ueno, NT; Valero, V; Willey, JS; Wu, J | 1 |
1 review(s) available for lapatinib and entinostat
| Article | Year |
|---|---|
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
1 trial(s) available for lapatinib and entinostat
| Article | Year |
|---|---|
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Breast Neoplasms, Male; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Pyridines; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2019 |
3 other study(ies) available for lapatinib and entinostat
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Chromatography, Liquid; Drug Interactions; Lapatinib; Male; Mass Spectrometry; Pyridines; Quinazolines; Rats; Rats, Sprague-Dawley | 2014 |
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |